Catalyst Pharmaceuticals Inc (CPRX)
20.60
-1.09
(-5.03%)
USD |
NASDAQ |
Nov 15, 16:00
20.81
+0.21
(+1.02%)
Pre-Market: 20:00
Catalyst Pharmaceuticals Research and Development Expense (TTM): 10.82M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 10.82M |
| June 30, 2024 | 91.20M |
| March 31, 2024 | 92.17M |
| December 31, 2023 | 93.15M |
| September 30, 2023 | 95.27M |
| June 30, 2023 | 19.92M |
| March 31, 2023 | 19.95M |
| December 31, 2022 | 19.79M |
| September 30, 2022 | 20.69M |
| June 30, 2022 | 16.86M |
| March 31, 2022 | 17.33M |
| December 31, 2021 | 16.94M |
| September 30, 2021 | 16.12M |
| June 30, 2021 | 15.38M |
| March 31, 2021 | 15.28M |
| December 31, 2020 | 16.50M |
| September 30, 2020 | 18.63M |
| June 30, 2020 | 19.48M |
| March 31, 2020 | 19.76M |
| December 31, 2019 | 18.84M |
| September 30, 2019 | 20.95M |
| June 30, 2019 | 20.89M |
| March 31, 2019 | 19.97M |
| December 31, 2018 | 19.92M |
| September 30, 2018 | 14.91M |
| Date | Value |
|---|---|
| June 30, 2018 | 13.07M |
| March 31, 2018 | 11.82M |
| December 31, 2017 | 11.38M |
| September 30, 2017 | 10.79M |
| June 30, 2017 | 10.58M |
| March 31, 2017 | 10.64M |
| December 31, 2016 | 11.37M |
| September 30, 2016 | 12.38M |
| June 30, 2016 | 12.93M |
| March 31, 2016 | 13.00M |
| December 31, 2015 | 11.80M |
| September 30, 2015 | 10.35M |
| June 30, 2015 | 10.20M |
| March 31, 2015 | 9.719M |
| December 31, 2014 | 10.12M |
| September 30, 2014 | 9.802M |
| June 30, 2014 | 9.720M |
| March 31, 2014 | 9.753M |
| December 31, 2013 | 8.097M |
| September 30, 2013 | 6.773M |
| June 30, 2013 | 4.624M |
| March 31, 2013 | 3.025M |
| December 31, 2012 | 2.660M |
| September 30, 2012 | 2.875M |
| June 30, 2012 | 2.834M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
10.82M
Minimum
Sep 2024
95.27M
Maximum
Sep 2023
32.70M
Average
19.16M
Median
Research and Development Expense (TTM) Benchmarks
| Corcept Therapeutics Inc | 231.29M |
| Vertex Pharmaceuticals Inc | 3.456B |
| Sarepta Therapeutics Inc | 800.09M |
| ADMA Biologics Inc | 1.868M |
| BioVie Inc | 23.10M |